Real-time PCR testing for bla KPC , bla NDM , bla VIM , bla IMP , and bla CTX-M was performed on rectal swabs 23 obtained from residents of two long-term acute care facilities. While bla KPC was detected in 69/102 24 (67.6%), testing for four other targets increased the positivity rate for a broad-spectrum β-lactamase to 25 73.5% (McNemar p=0.03) . 26 27 on June 30, 2017 by guest http://jcm.asm.org/
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Increased resistance to multiple antimicrobial agents is of growing concern worldwide and is now 28 considered the greatest threat to human health (1). Increasing concern is controlling spread in 29 healthcare systems, where the majority of resistance emerges or disseminates. Control is multifaceted, 30 including: 1) screening and isolation, 2) environmental disinfection, 3) antibiotic stewardship, 4) rapid 31 diagnosis and detection of resistance, 5) hand hygiene, 6) vaccination, 7) education, 8) research, 9) 32 communication and reporting of critical pathogens, and 10) outbreak tracking of emerging infections. 33
Effectively dealing with these 10 key infection control functions involves the laboratory in at least six 34 components; 1, 3, 4, 8, 9, and 10. Use of molecular methods can rapidly identify patients harboring 35 resistant pathogens as a critical first step in controlling the spread of multidrug resistant organisms 36 (MDROs), followed by proper patient isolation. Of particular concern is the frequent transfer of 37 residents from long-term care facilities who are colonized with MDROs into hospitals. Recently, we 38 identified Klebsiella pneumoniae carbapenemase (KPC)-containing Enterobacteriaceae, currently 39 referred to as carbapenem resistant Enterobacteriaceae, or CRE (2), in two-thirds of residents from two 40
Chicago-area long-term acute care facilities (LTACHs), but there was also culture evidence of resistant 41 bacteria that were not KPC-positive (3). Using bacterial lysis remaining after initial testing for bla KPC , time PCR testing for other β-lactamase genes was performed on these specimens to fully characterize 43 the prevalence of MDROs in this select high-risk population. Real-time PCR: After the analysis for bla KPD was completed (3), the remaining lysis supernatant from the 57 original bla kpc point prevalence specimens were tested for the antibiotic resistance genes bla CTX-M , 58 bla NDM , bla IMP , and bla VIM to determine if any of these were responsible for the observed non-KPC 59 resistance (3). Two µL of the original lysis supernatant per reaction was used for real-time PCR 60 performed on a LightCycler 1.5 or 2.0 Instrument (Roche Diagnostics, Indianapolis, IN). The primers, 61 probes and PCR parameters are listed in Table 1 . The assay for bla KPC was previously published from our 62 laboratory (4); all other assays for this study were designed and validated in our laboratory except for 63 bla IMP and bla VIM , which was modified from Bisiklis et al. to accommodate a SYBR green assay (5). 64
Validation of each assay included the detection of isolates known to contain the antibiotic resistance 65 gene in a blind analysis with negative specimens; the isolation of Gram-negative bacilli from enrichment 66 broths that phenotypically matched the appropriate antibiotic resistance profile; and, in the case of 67 bla CTX-M , the sequencing of amplicons to determine the specificity of the CTX-M Group 1 assay versus the 68 CTX-M global assay. 69
Statistics: The McNemar's test was used to compare paired proportions between testing for one target 70 and testing for multiple targets. 71
Real-time PCR testing was negative for the genes bla NDM and bla IMP . As previously reported, bla KPC MDRO is found. We continually monitor for any organism transmission using contact tracing and pulsed-83 field gel electrophoresis (PFGE); to date only one transmission to an existing patient has been detected 84 during nearly 4 years of persistent transmission risk. 85
This study has some limitations, including small sample size. Additionally, ceftazidime was chosen as the 86 antibiotic included in the broth incubation to enrich for CRE such as those harboring bla KPC , the primary 87 target of the point prevalence study. This antibiotic choice may limit the growth of bacteria with 88 extended spectrum β-lactamases (ESBLs) like bla CTX-M , resulting in a possible underestimation of ESBL-89 carriage in this study. Therefore, substituting ceftriaxone for ceftazidime could enhance the recovery of 90 bla CTX-M for future surveillance testing. Preliminary testing of this change in our current surveillance 91 protocol yields more bacterial growth in the overnight enrichment broth, which has in turn resulted in 92 increased background fluorescence observed in the SYBR green assay for bla IMP and bla VIM . To counteract 93 this complication, we are now validating the probe-based assay as originally published by Bisiklis et al. 94 (5) . 95 and labor required to test for these targets. The assay for bla IMP and bla VIM , regardless whether it is 99 performed as a SYBR green assay or as a probe assay, cannot be multiplexed with the others due to 100 distinctly different PCR parameters. Thus, the surveillance protocol as described is possible using only 101 two real-time PCR assays per sample. 102
The goal of surveillance testing is to identify patients with MDRO to facilitate early isolation. Our initial 103 investigation found real-time PCR is significantly more sensitive and faster than culture (3), suggesting 104 PCR currently is the optimal assay for MDRO surveillance. We have demonstrated multiple extended 105 spectrum β-lactamases can be detected using PCR as part of a comprehensive infection control 106
program. In conclusion, we demonstrated that MDROs often harbor multiple resistance genes and when 107 detection of multiple MDRO gene targets is indicated, specific molecular testing can be utilized as 108 multiple individual PCR assays, or as one or two multiplexed assays. . 109 Table 1 
